Quality of Life Among Hospitalized Fibromyalgia Older Adults: a Case-Control Study.

IF 1.6 Q4 GERIATRICS & GERONTOLOGY

Canadian Geriatrics Journal Pub Date : 2024-09-05 eCollection Date: 2024-09-01 DOI:10.5770/cgj.27.724

Abdallah Fawaz, Mouhamad Suliman, Mor Robin, Shay Brikman, Nogah Shabshin, Irina Novofastovsky, Mohammad Egbaria, Reuven Mader, Amir Bieber

{"title":"Quality of Life Among Hospitalized Fibromyalgia Older Adults: a Case-Control Study.","authors":"Abdallah Fawaz, Mouhamad Suliman, Mor Robin, Shay Brikman, Nogah Shabshin, Irina Novofastovsky, Mohammad Egbaria, Reuven Mader, Amir Bieber","doi":"10.5770/cgj.27.724","DOIUrl":null,"url":null,"abstract":"Background: Only few studies addressed the topic of Fibromyalgia Syndrome (FMS) effects on geriatric population quality of life and drug usage. The objective of this study was to demonstrate the significant impact of FMS in terms of quality of life (QOL) in geriatric aged patients.Methods: 80 patients were studied, 40 with FMS according to FMS 2016 classification criteria, and 40 non-FMS controls. The patients were all above the age of 65 years. The FMS and control group completed Widespread Pain Index (WPI) and Symptom Severity Score (SSS). Three questionnaires, Fibromyalgia Impact Questionnaire (FIQ), Short Form (SF-36) Questionnaire, and Health Assessment Questionnaire Disability Index (HAQ-DI) were completed. These with additional medical records were used to classify symptoms and severity in both groups.Results: Fibromyalgia patients demonstrated significant higher disability scores, (FIQ of 79.5 vs. 33.9, p<.01, and HAQ-DI of 2.00 vs. 1.00, p<.01 for FMS vs. non-FMS, respectively), and lower social functioning in comparison to non-FMS controls (SF-36 of social functioning 0.31 vs. 0.92, p<.01 for FMS vs. non-FMS, respectively). The FMS group had a higher use of pain management medications (opioid use of 12 patients vs. 0, p<.01, use of non-steroidal anti-inflammatory drugs by 11 FMS patients vs. 4 non-FMS controls, p<.01).Conclusions: Patients with FMS older than 65 years of age demonstrate poorer outcomes and worse symptoms in comparison to matched-aged non-FMS control group. An association was found between FMS and the effect on the quality of life in this population.","PeriodicalId":56182,"journal":{"name":"Canadian Geriatrics Journal","volume":"27 3","pages":"268-274"},"PeriodicalIF":1.6000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346624/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Geriatrics Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5770/cgj.27.724","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Only few studies addressed the topic of Fibromyalgia Syndrome (FMS) effects on geriatric population quality of life and drug usage. The objective of this study was to demonstrate the significant impact of FMS in terms of quality of life (QOL) in geriatric aged patients.

Methods: 80 patients were studied, 40 with FMS according to FMS 2016 classification criteria, and 40 non-FMS controls. The patients were all above the age of 65 years. The FMS and control group completed Widespread Pain Index (WPI) and Symptom Severity Score (SSS). Three questionnaires, Fibromyalgia Impact Questionnaire (FIQ), Short Form (SF-36) Questionnaire, and Health Assessment Questionnaire Disability Index (HAQ-DI) were completed. These with additional medical records were used to classify symptoms and severity in both groups.

Results: Fibromyalgia patients demonstrated significant higher disability scores, (FIQ of 79.5 vs. 33.9, p<.01, and HAQ-DI of 2.00 vs. 1.00, p<.01 for FMS vs. non-FMS, respectively), and lower social functioning in comparison to non-FMS controls (SF-36 of social functioning 0.31 vs. 0.92, p<.01 for FMS vs. non-FMS, respectively). The FMS group had a higher use of pain management medications (opioid use of 12 patients vs. 0, p<.01, use of non-steroidal anti-inflammatory drugs by 11 FMS patients vs. 4 non-FMS controls, p<.01).

Conclusions: Patients with FMS older than 65 years of age demonstrate poorer outcomes and worse symptoms in comparison to matched-aged non-FMS control group. An association was found between FMS and the effect on the quality of life in this population.

查看原文本刊更多论文

住院纤维肌痛老年人的生活质量：一项病例对照研究。

背景：只有少数研究涉及纤维肌痛综合征（FMS）对老年群体生活质量和药物使用的影响。本研究的目的是证明 FMS 对老年患者生活质量（QOL）的重大影响。方法：研究对象为 80 名患者，其中 40 名根据 FMS 2016 年分类标准患有 FMS，40 名未患有 FMS。患者年龄均在 65 岁以上。FMS组和对照组均填写了广泛性疼痛指数（WPI）和症状严重程度评分（SSS）。他们还填写了三份问卷：纤维肌痛影响问卷（FIQ）、简表（SF-36）问卷和健康评估问卷残疾指数（HAQ-DI）。结果显示，纤维肌痛患者的症状和严重程度明显高于其他患者：结果：纤维肌痛患者的残疾评分明显更高（FIQ 为 79.5 分，而 FMS 为 33.9 分）：与年龄相仿的非纤维肌痛对照组相比，65 岁以上的纤维肌痛患者的治疗效果更差，症状更严重。研究发现，FMS 与该人群生活质量的影响之间存在关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Canadian Geriatrics Journal Nursing-Gerontology

CiteScore

5.20

自引率

0.00%

发文量

期刊介绍： The Canadian Geriatrics Journal (CGJ) is a peer-reviewed publication that is a home for innovative aging research of a high quality aimed at improving the health and the care provided to older persons residing in Canada and outside our borders. While we gratefully accept submissions from researchers outside our country, we are committed to encouraging aging research by Canadians. The CGJ is targeted to family physicians with training or an interest in the care of older persons, specialists in geriatric medicine, geriatric psychiatrists, and members of other health disciplines with a focus on gerontology.